riverbiomedics – River Biomedics

Home
Drug Discovery
Technology
About Us
Publications
News
Career
Contact

Home
Drug Discovery
Technology
About Us
Publications
News
Career
Contact

By

riverbiomedics

16

Dec

Milestone Achieved: We’ve successfully identified active compounds in our 2D cardiomyocyte assay.

16th December 2024riverbiomedicsNews

11

Dec

First-in-Class Disease-Modifying Approach to Heart Failure

11th December 2024riverbiomedicsNews

29

Nov

CEO Nicky Cooper, attending BioFIT 2024 conference on 3rd/4th December.

29th November 2024riverbiomedicsNews

04

Nov

Annual Consortium Meeting of the BioRobot-Mini Heart Project

4th November 2024riverbiomedicsNews

22

Oct

ELM Portfolio Meeting, Saarbrücken, Germany

22nd October 2024riverbiomedicsNews

24

Sep

ELM Portfolio Meeting 2 at INM-Leibniz Institute for New Materials, Saarbrücken, Germany

24th September 2024riverbiomedicsNews

26

Aug

We’re featured on the Innovation Radar’s website as Key Innovator!

26th August 2024riverbiomedicsNews

16

Aug

River BioMedics strengthens drug discovery team working with RGDscience

16th August 2024riverbiomedicsNews

14

Jun

Professor John McMurray joins us as a scientific advisor on our lead programme

14th June 2024riverbiomedicsNews

01

May

Dr Clare Murray join us as a drug discovery consultant

1st May 2024riverbiomedicsNews

1 2 3 4

About Us

River BioMedics is a Dutch biotech company focused on cardiac drug discovery.

Recent Posts

Milestone Achieved: We’ve successfully identified active compounds in our 2D cardiomyocyte assay.
First-in-Class Disease-Modifying Approach to Heart Failure
CEO Nicky Cooper, attending BioFIT 2024 conference on 3rd/4th December.
Annual Consortium Meeting of the BioRobot-Mini Heart Project

RIVER BIOMEDICS 2021, ALL RIGHTS RESERVED, KVK 71357637